TYRO3 and neoplasm: In the BRAF and RNF43 tumours, co-occurring mutations were observed in ACVR2A (FDR-adjusted P = 0.06) in HM tumours, and AKT1 (FDR-adjusted P = 0.03) and TYRO3 (FDR-adjusted P = 0.08) in the nHM tumours (Extended Data Fig. 1b).